human non small cell lung cancer nsclc cell lines a549 (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
99
Structured Review
ATCC
human non small cell lung cancer nsclc cell lines a549
Human Non Small Cell Lung Cancer Nsclc Cell Lines A549, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 9081 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+non+small+cell+lung+cancer+nsclc+cell+lines+a549/A549/pm41946943-73-0-15
Average 99 stars, based on 9081 article reviews
Human Non Small Cell Lung Cancer Nsclc Cell Lines A549, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 9081 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+non+small+cell+lung+cancer+nsclc+cell+lines+a549/A549/pm41946943-73-0-15
Average 99 stars, based on 9081 article reviews
human non small cell lung cancer nsclc cell lines a549 - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
Isolation:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and RNA Sequencing:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Control:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Invasion Assay:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Staining:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Gene Expression:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Migration:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Western Blot:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Cell Culture:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Fluorescence:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Microscopy:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Derivative Assay:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Resazurin Assay:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Marker:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Expressing:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Proliferation Assay:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Colony Assay:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Activity Assay:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Comparison:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Liquid Chromatography with Mass Spectroscopy:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Mass Spectrometry:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Software:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Glycoproteomics:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and ATP Assay:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Cell Cycle Assay:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and ROS Assay:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Flow Cytometry:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Immunofluorescence:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and CRISPR:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Gene Knockout:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Generated:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Knock-Out:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Lysis:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Recombinant:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Quantitative Proteomics:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Two Tailed Test:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and MANN-WHITNEY:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Incubation:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Concentration Assay:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Clonogenic Assay:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Cell Attachment Assay:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Standard Deviation:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Confocal Microscopy:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Membrane:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Transfection:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Transwell Assay:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Knockdown:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and In Vitro:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and In Vivo:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Transwell Invasion Assay:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and Injection:Article Title: Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Article Snippet: Human non-small cell lung cancer (NSCLC) cell lines A549, Calu-6, NCI-H520, NCI-H727, NCI-H838, NCI-H1299, NCI-H1437, NCI-H1793, NCI-H1869, NCI-H2122 and |
